| Symbol | PEPG |
|---|---|
| Name | PEPGEN INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 321 HARRISON AVENUE,8TH FLOOR, BOSTON, Massachusetts, 02118, United States |
| Telephone | +1 781 797-0979 |
| Fax | — |
| — | |
| Website | https://www.pepgen.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001835597 |
| Description | PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Additional info from NASDAQ: |
Kasraian Kasra 🔴 sold 1.2K shares of PepGen Inc. (PEPG) at $1.41 Transaction Date: May 21, 2026 | Filing ID: 239506
Read moreNew Form EFFECT - PepGen Inc. <b>Filed:</b> 2026-05-21 <b>AccNo:</b> 9999999995-26-001734 <b>Size:</b> 1 KB
Read morePepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
Read moreNew Form S-3 - PepGen Inc. <b>Filed:</b> 2026-05-18 <b>AccNo:</b> 0001193125-26-228960 <b>Size:</b> 1 MB
Read moreNew Form SCHEDULE 13G/A - PepGen Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001831942-26-000023 <b>Size:</b> 15 KB
Read morePepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG
Read moreNew Form ARS - PepGen Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001193125-26-187036 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - PepGen Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001193125-26-186949 <b>Size:</b> 1 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07220603 | An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy T… | Phase2 | Myotonic Dystrophy 1 | Recruiting | 2025-12-23 | 2029-01-01 | ClinicalTrials.gov |
| NCT06833931 | A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amen… | Phase2 | Duchenne Muscular Dystrophy (DMD) | Withdrawn | 2024-12-17 | 2025-05-28 | ClinicalTrials.gov |
| NCT06667453 | A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 | Phase2 | Myotonic Dystrophy 1 | Recruiting | 2024-12-10 | 2027-03-01 | ClinicalTrials.gov |
| NCT06079736 | A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable … | Phase2 | Duchenne Muscular Dystrophy | Terminated | 2024-01-03 | 2025-08-28 | ClinicalTrials.gov |
| NCT06204809 | Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myoto… | Phase1 | Myotonic Dystrophy 1 | Completed | 2023-12-12 | 2025-10-28 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Duchenne Muscular Dystrophy (DMD) | WITHDRAWN | NCT06833931 |
| IV infusion | Other | Phase PHASE2 | Duchenne Muscular Dystrophy (DMD) | WITHDRAWN | NCT06833931 |
| PGN-EDO51 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | TERMINATED | NCT06079736 |
| Placebo | Other | Phase PHASE1 | Myotonic Dystrophy 1 | COMPLETED | NCT06204809 |
| PGN-EDODM1 for infusion | Other | Phase PHASE1 | Myotonic Dystrophy 1 | COMPLETED | NCT06204809 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT07220603 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| Placebo | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| PGN-EDODM1 | Other | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT06667453 |
| IV infusion | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy (DMD) | WITHDRAWN | NCT06833931 |
| PGN-EDODM1 | DRUG | Phase PHASE2 | Myotonic Dystrophy 1 | RECRUITING | NCT07220603 |
| Placebo | OTHER | Phase PHASE2 | Duchenne Muscular Dystrophy (DMD) | WITHDRAWN | NCT06833931 |
| PGN-EDODM1 for infusion | DRUG | Phase PHASE1 | Myotonic Dystrophy 1 | COMPLETED | NCT06204809 |
| PGN-EDO51 | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy | TERMINATED | NCT06079736 |